Exelixis | EXEL - Ebit

Stock Price
44.81
Daily Change
0.80 1.82%
Monthly
2.75%
Yearly
21.37%
Q1 Forecast
42.28

Exelixis reported $235.91M in EBIT for its fiscal quarter ending in December of 2025.





Ebit Change Date
Acadia Pharmaceuticals USD 35.76M 3.38M Sep/2025
Agios Pharmaceuticals USD -121.58M 4.71M Dec/2025
Akebia Therapeutics USD 13.51M 27.82M Mar/2025
Amgen USD 3.96B 464M Dec/2025
AstraZeneca USD 2.97B 4.48B Dec/2025
Bayer EUR -399M 363M Sep/2025
BioMarin Pharmaceutical USD 198.39M 230.08M Dec/2025
Bristol-Myers Squibb USD 3.47B 567M Dec/2025
Cytokinetics USD -166.76M 55.25M Sep/2025
Eisai JPY 20.03B 6.36B Dec/2025
Eli Lilly USD 8.99B 1.57B Dec/2025
Esperion Therapeutics USD -16.03M 11.51M Sep/2024
Exelixis USD 235.91M 20.45M Dec/2025
Genmab DKK 432M 900.27M Jun/2025
Glaxosmithkline GBP 3.76B 1.69B Sep/2025
Incyte USD 383.88M 47.44M Dec/2025
Ionis Pharmaceuticals USD -160.18M 304.96M Sep/2025
MacroGenics USD 20.16M 55.51M Sep/2025
Merck USD 6.24B 1.32B Dec/2025
Moderna USD -857M 597M Dec/2025
Nektar Therapeutics USD -34.34M 3.68M Sep/2024
Neurocrine Biosciences USD 227.9M 11.4M Dec/2025
Novartis USD -9.19B 13.87B Jun/2025
Pfizer USD 4.65B 71M Dec/2025
Puma Biotechnology USD -2.2M 11.41M Jun/2024
Sanofi EUR 3.74B 2.23B Sep/2025
Takeda JPY 257.49B 568.56B Dec/2025
Ultragenyx Pharmaceutical USD -114M 56.89M Dec/2025
Xencor USD -47.52M 24.69M Sep/2025